These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 20678715)

  • 21. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
    Peng CT; Tsai CH; Wu KH
    Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined iron chelation therapy.
    Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
    Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.
    Aydinok Y; Ulger Z; Nart D; Terzi A; Cetiner N; Ellis G; Zimmermann A; Manz C
    Haematologica; 2007 Dec; 92(12):1599-606. PubMed ID: 18055982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent developments in iron chelation therapy.
    Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
    Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major.
    Farmaki K; Angelopoulos N; Anagnostopoulos G; Gotsis E; Rombopoulos G; Tolis G
    Br J Haematol; 2006 Aug; 134(4):438-44. PubMed ID: 16822284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult beta-thalassemia major patients.
    Tsiapras D; Fragatou S; Farmaki K; Kyrzopoulos S; Paraskevaidis I; Voudris V; Kremastinos D
    Hemoglobin; 2010 Jun; 34(3):210-20. PubMed ID: 20524811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH; Chen X; Wu CC; Wu KH; Song TS; Weng TF; Hsieh YW; Peng CT
    Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia.
    Kuo KH; Mrkobrada M
    Hemoglobin; 2014; 38(6):409-21. PubMed ID: 25307964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
    Huang YC; Chang JS; Wu KH; Peng CT
    Hemoglobin; 2006; 30(2):229-38. PubMed ID: 16798648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2010 Jun; 34(3):204-9. PubMed ID: 20524810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial.
    Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
    Br J Haematol; 2009 Apr; 145(2):245-54. PubMed ID: 19236376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens.
    Christoforidis A; Haritandi A; Tsatra I; Tsitourides I; Karyda S; Athanassiou-Metaxa M
    Eur J Haematol; 2007 Jan; 78(1):52-7. PubMed ID: 17042760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications.
    Chuang TY; Li JP; Weng TF; Wu KH; Chao YH
    Ann Hematol; 2020 Oct; 99(10):2289-2294. PubMed ID: 32737633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Pibiri M; Nair SV; Walker JM; Pennell DJ
    J Cardiovasc Magn Reson; 2008 Feb; 10(1):12. PubMed ID: 18298856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.